COVID-19 preclinical drug discovery and development

The Academy has launched a new survey and database to map ongoing and emerging COVID-19 preclinical drug development research activities to help researchers and funders identify opportunities for collaboration, avoid duplication of effort and prioritise the most promising research.

The Academy has launched a new survey and database to map ongoing and emerging COVID-19 preclinical drug development research activities to help researchers and funders identify opportunities for collaboration, avoid duplication of effort and prioritise the most promising research. The survey and database can both be found at http://covidpipeline.acmedsci.ac.uk/

                                             

The COVID-19 pandemic presents an unprecedented challenge for society and it is vital that biomedical and health research rises to this challenge to help mitigate the effects of the pandemic, save lives and prevent any reoccurrence. The UK’s outstanding life sciences sector will enable it to make a significant contribution to the global research effort to tackle the COVID-19 pandemic through drug discovery research and its intimate alignment with clinical programmes.

This rapid response project is mapping the landscape of COVID-19 preclinical drug discovery and development across the UK and beyond. We have produced a resource that will provide a comprehensive overview of preclinical research into developing novel therapeutic targets, new molecular entities and repurposing existing medicines. This resource will enable researchers and funders to quickly identify opportunities for collaboration, avoid duplication of effort and prioritise the most promising research.

This project is being driven by a group of experts with a broad range of research expertise and experience. More details on this group can be found in the 'Expert group' tab.

Depending on the outcome of this mapping exercise, the project may expand its remit beyond this to include a coordinating role as the drug development response to COVID-19 rapidly ramps up.

 

Key contacts


Multimorbidity: Cross-sector opportunities for developing new interventions for patients with multiple long-term conditions

Book Now

Webinar: Addressing the threat of antimalarial drug resistance to malaria elimination in Southeast Asia

Book Now

The Academy of Medical Sciences and The Lancet International Health Lecture 2020

Book Now
View more
 
 
 
 
 
 
FB Twitter Instagram Youtube